Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study

Kathleen E. Squires, Linda Gail Bekker, Joseph J. Eron, Benjamin Cheng, Juergen K. Rockstroh, Farid Marquez, Princy Kumar, Melanie Thompson, Rafael E Campo, Karam Mounzer, Kim M. Strohmaier, Chengxing Lu, Anthony Rodgers, Beth E. Jackson, Larissa A. Wenning, Michael Robertson, Bach Yen T Nguyen, Peter Sklar

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The racial diversity and gender distribution of HIV-infected patients make it essential to confirm the safety and efficacy of raltegravir in these populations. A multicenter, open-label, single-arm observational study was conducted in a diverse cohort of HIV-infected patients (goals: ≥25% women; ≥50% blacks in the United States), enrolling treatment-experienced patients failing or intolerant to current antiretroviral therapy (ART) and treatment-naive patients (limited to ≤20%). All patients received raltegravir 400 mg b.i.d. in a combination antiretroviral regimen for up to 48 weeks. A total of 206 patients received study treatment at 34 sites in the United States, Brazil, Dominican Republic, Jamaica, and South Africa: 97 (47%) were female and 153 (74%) were black [116 (56%) in the United States]. Of these, 185 patients were treatment experienced: 97 (47%) were failing and 88 (43%) were intolerant to current therapy; 21 patients (10%) were treatment naive. Among treatment-intolerant patients, 55 (63%) had HIV-1 RNA<50 copies/ml at baseline. Overall, 15% of patients discontinued: 13% of men, 18% of women, 14% of blacks, and 17% of nonblacks. At week 48, HIV RNA was <50 copies/ml in 60/94 (64%) patients failing prior therapy, 61/80 (76%) patients intolerant to prior therapy, and 16/21 (76%) treatment-naive patients. Response rates were similar for men vs. women and black vs. nonblack patients. Drug-related clinical adverse events were reported by 8% of men, 18% of women, 14% of blacks, and 9% of nonblacks. After 48 weeks of treatment in a diverse cohort of HIV-infected patients, raltegravir was generally safe and well tolerated with potent efficacy regardless of gender or race.

Original languageEnglish
Pages (from-to)859-870
Number of pages12
JournalAIDS Research and Human Retroviruses
Volume29
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

HIV
Safety
Therapeutics
Raltegravir Potassium
Dominican Republic
RNA
Jamaica
South Africa
Observational Studies
Brazil
HIV-1

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients : 48-week results from the REALMRK study. / Squires, Kathleen E.; Bekker, Linda Gail; Eron, Joseph J.; Cheng, Benjamin; Rockstroh, Juergen K.; Marquez, Farid; Kumar, Princy; Thompson, Melanie; Campo, Rafael E; Mounzer, Karam; Strohmaier, Kim M.; Lu, Chengxing; Rodgers, Anthony; Jackson, Beth E.; Wenning, Larissa A.; Robertson, Michael; Nguyen, Bach Yen T; Sklar, Peter.

In: AIDS Research and Human Retroviruses, Vol. 29, No. 6, 01.06.2013, p. 859-870.

Research output: Contribution to journalArticle

Squires, KE, Bekker, LG, Eron, JJ, Cheng, B, Rockstroh, JK, Marquez, F, Kumar, P, Thompson, M, Campo, RE, Mounzer, K, Strohmaier, KM, Lu, C, Rodgers, A, Jackson, BE, Wenning, LA, Robertson, M, Nguyen, BYT & Sklar, P 2013, 'Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study', AIDS Research and Human Retroviruses, vol. 29, no. 6, pp. 859-870. https://doi.org/10.1089/aid.2012.0292
Squires, Kathleen E. ; Bekker, Linda Gail ; Eron, Joseph J. ; Cheng, Benjamin ; Rockstroh, Juergen K. ; Marquez, Farid ; Kumar, Princy ; Thompson, Melanie ; Campo, Rafael E ; Mounzer, Karam ; Strohmaier, Kim M. ; Lu, Chengxing ; Rodgers, Anthony ; Jackson, Beth E. ; Wenning, Larissa A. ; Robertson, Michael ; Nguyen, Bach Yen T ; Sklar, Peter. / Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients : 48-week results from the REALMRK study. In: AIDS Research and Human Retroviruses. 2013 ; Vol. 29, No. 6. pp. 859-870.
@article{af6aeeae91ee4e6db835c52078999514,
title = "Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study",
abstract = "The racial diversity and gender distribution of HIV-infected patients make it essential to confirm the safety and efficacy of raltegravir in these populations. A multicenter, open-label, single-arm observational study was conducted in a diverse cohort of HIV-infected patients (goals: ≥25{\%} women; ≥50{\%} blacks in the United States), enrolling treatment-experienced patients failing or intolerant to current antiretroviral therapy (ART) and treatment-naive patients (limited to ≤20{\%}). All patients received raltegravir 400 mg b.i.d. in a combination antiretroviral regimen for up to 48 weeks. A total of 206 patients received study treatment at 34 sites in the United States, Brazil, Dominican Republic, Jamaica, and South Africa: 97 (47{\%}) were female and 153 (74{\%}) were black [116 (56{\%}) in the United States]. Of these, 185 patients were treatment experienced: 97 (47{\%}) were failing and 88 (43{\%}) were intolerant to current therapy; 21 patients (10{\%}) were treatment naive. Among treatment-intolerant patients, 55 (63{\%}) had HIV-1 RNA<50 copies/ml at baseline. Overall, 15{\%} of patients discontinued: 13{\%} of men, 18{\%} of women, 14{\%} of blacks, and 17{\%} of nonblacks. At week 48, HIV RNA was <50 copies/ml in 60/94 (64{\%}) patients failing prior therapy, 61/80 (76{\%}) patients intolerant to prior therapy, and 16/21 (76{\%}) treatment-naive patients. Response rates were similar for men vs. women and black vs. nonblack patients. Drug-related clinical adverse events were reported by 8{\%} of men, 18{\%} of women, 14{\%} of blacks, and 9{\%} of nonblacks. After 48 weeks of treatment in a diverse cohort of HIV-infected patients, raltegravir was generally safe and well tolerated with potent efficacy regardless of gender or race.",
author = "Squires, {Kathleen E.} and Bekker, {Linda Gail} and Eron, {Joseph J.} and Benjamin Cheng and Rockstroh, {Juergen K.} and Farid Marquez and Princy Kumar and Melanie Thompson and Campo, {Rafael E} and Karam Mounzer and Strohmaier, {Kim M.} and Chengxing Lu and Anthony Rodgers and Jackson, {Beth E.} and Wenning, {Larissa A.} and Michael Robertson and Nguyen, {Bach Yen T} and Peter Sklar",
year = "2013",
month = "6",
day = "1",
doi = "10.1089/aid.2012.0292",
language = "English",
volume = "29",
pages = "859--870",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients

T2 - 48-week results from the REALMRK study

AU - Squires, Kathleen E.

AU - Bekker, Linda Gail

AU - Eron, Joseph J.

AU - Cheng, Benjamin

AU - Rockstroh, Juergen K.

AU - Marquez, Farid

AU - Kumar, Princy

AU - Thompson, Melanie

AU - Campo, Rafael E

AU - Mounzer, Karam

AU - Strohmaier, Kim M.

AU - Lu, Chengxing

AU - Rodgers, Anthony

AU - Jackson, Beth E.

AU - Wenning, Larissa A.

AU - Robertson, Michael

AU - Nguyen, Bach Yen T

AU - Sklar, Peter

PY - 2013/6/1

Y1 - 2013/6/1

N2 - The racial diversity and gender distribution of HIV-infected patients make it essential to confirm the safety and efficacy of raltegravir in these populations. A multicenter, open-label, single-arm observational study was conducted in a diverse cohort of HIV-infected patients (goals: ≥25% women; ≥50% blacks in the United States), enrolling treatment-experienced patients failing or intolerant to current antiretroviral therapy (ART) and treatment-naive patients (limited to ≤20%). All patients received raltegravir 400 mg b.i.d. in a combination antiretroviral regimen for up to 48 weeks. A total of 206 patients received study treatment at 34 sites in the United States, Brazil, Dominican Republic, Jamaica, and South Africa: 97 (47%) were female and 153 (74%) were black [116 (56%) in the United States]. Of these, 185 patients were treatment experienced: 97 (47%) were failing and 88 (43%) were intolerant to current therapy; 21 patients (10%) were treatment naive. Among treatment-intolerant patients, 55 (63%) had HIV-1 RNA<50 copies/ml at baseline. Overall, 15% of patients discontinued: 13% of men, 18% of women, 14% of blacks, and 17% of nonblacks. At week 48, HIV RNA was <50 copies/ml in 60/94 (64%) patients failing prior therapy, 61/80 (76%) patients intolerant to prior therapy, and 16/21 (76%) treatment-naive patients. Response rates were similar for men vs. women and black vs. nonblack patients. Drug-related clinical adverse events were reported by 8% of men, 18% of women, 14% of blacks, and 9% of nonblacks. After 48 weeks of treatment in a diverse cohort of HIV-infected patients, raltegravir was generally safe and well tolerated with potent efficacy regardless of gender or race.

AB - The racial diversity and gender distribution of HIV-infected patients make it essential to confirm the safety and efficacy of raltegravir in these populations. A multicenter, open-label, single-arm observational study was conducted in a diverse cohort of HIV-infected patients (goals: ≥25% women; ≥50% blacks in the United States), enrolling treatment-experienced patients failing or intolerant to current antiretroviral therapy (ART) and treatment-naive patients (limited to ≤20%). All patients received raltegravir 400 mg b.i.d. in a combination antiretroviral regimen for up to 48 weeks. A total of 206 patients received study treatment at 34 sites in the United States, Brazil, Dominican Republic, Jamaica, and South Africa: 97 (47%) were female and 153 (74%) were black [116 (56%) in the United States]. Of these, 185 patients were treatment experienced: 97 (47%) were failing and 88 (43%) were intolerant to current therapy; 21 patients (10%) were treatment naive. Among treatment-intolerant patients, 55 (63%) had HIV-1 RNA<50 copies/ml at baseline. Overall, 15% of patients discontinued: 13% of men, 18% of women, 14% of blacks, and 17% of nonblacks. At week 48, HIV RNA was <50 copies/ml in 60/94 (64%) patients failing prior therapy, 61/80 (76%) patients intolerant to prior therapy, and 16/21 (76%) treatment-naive patients. Response rates were similar for men vs. women and black vs. nonblack patients. Drug-related clinical adverse events were reported by 8% of men, 18% of women, 14% of blacks, and 9% of nonblacks. After 48 weeks of treatment in a diverse cohort of HIV-infected patients, raltegravir was generally safe and well tolerated with potent efficacy regardless of gender or race.

UR - http://www.scopus.com/inward/record.url?scp=84877862377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877862377&partnerID=8YFLogxK

U2 - 10.1089/aid.2012.0292

DO - 10.1089/aid.2012.0292

M3 - Article

C2 - 23351187

AN - SCOPUS:84877862377

VL - 29

SP - 859

EP - 870

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 6

ER -